[go: up one dir, main page]

EA200500671A1 - Фармацевтический состав оланзапина - Google Patents

Фармацевтический состав оланзапина

Info

Publication number
EA200500671A1
EA200500671A1 EA200500671A EA200500671A EA200500671A1 EA 200500671 A1 EA200500671 A1 EA 200500671A1 EA 200500671 A EA200500671 A EA 200500671A EA 200500671 A EA200500671 A EA 200500671A EA 200500671 A1 EA200500671 A1 EA 200500671A1
Authority
EA
Eurasian Patent Office
Prior art keywords
olanzapin
pharmaceutical composition
olanzapine
monosaccharide
oligosaccharide
Prior art date
Application number
EA200500671A
Other languages
English (en)
Other versions
EA008516B1 (ru
Inventor
Станка Перц
Иванка Банко
Иванка Коленц
Original Assignee
Крка Товарна Здравил, Д. Д., Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32173824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200500671(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Крка Товарна Здравил, Д. Д., Ново Место filed Critical Крка Товарна Здравил, Д. Д., Ново Место
Publication of EA200500671A1 publication Critical patent/EA200500671A1/ru
Publication of EA008516B1 publication Critical patent/EA008516B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Фармацевтический состав, содержащий гомогенную смесь (a) оланзапина или его фармацевтически приемлемой соли в качестве активного ингредиента, (b) моносахарида и/или олигосахарида, (c) полисахарида и необязательно дополнительных ингредиентов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500671A 2002-10-18 2003-10-16 Фармацевтический состав оланзапина EA008516B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200255A SI21303A (sl) 2002-10-18 2002-10-18 Farmacevtska formulacija olanzapina
PCT/SI2003/000036 WO2004035027A1 (en) 2002-10-18 2003-10-16 Pharmaceutical formulation of olanzapine

Publications (2)

Publication Number Publication Date
EA200500671A1 true EA200500671A1 (ru) 2005-10-27
EA008516B1 EA008516B1 (ru) 2007-06-29

Family

ID=32173824

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500671A EA008516B1 (ru) 2002-10-18 2003-10-16 Фармацевтический состав оланзапина

Country Status (18)

Country Link
US (2) US20050288276A1 (ru)
EP (1) EP1558219B1 (ru)
AT (1) ATE374600T1 (ru)
AU (1) AU2003269792A1 (ru)
CA (1) CA2502582C (ru)
CY (1) CY1107819T1 (ru)
DE (1) DE60316714T2 (ru)
DK (1) DK1558219T3 (ru)
EA (1) EA008516B1 (ru)
ES (1) ES2295626T3 (ru)
HR (1) HRP20050342B1 (ru)
NO (1) NO20052408L (ru)
PL (1) PL206217B1 (ru)
PT (1) PT1558219E (ru)
RS (1) RS51488B (ru)
SI (2) SI21303A (ru)
UA (1) UA89349C2 (ru)
WO (1) WO2004035027A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778183B1 (en) * 2004-08-18 2018-06-27 Synthon B.V. Liquid paroxetine compositions
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2013066280A1 (en) * 2011-10-31 2013-05-10 Mahmut Bilgic Water soluble antipsychotic formulations
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2083622B1 (ru) * 1970-03-27 1975-08-22 Sankyo Co
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
PL332503A1 (en) * 1996-09-24 1999-09-13 Lilly Co Eli Coated particles containing preparation
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
JP4530664B2 (ja) * 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
AU2002255196A1 (en) * 2002-04-18 2003-10-27 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions

Also Published As

Publication number Publication date
HRP20050342B1 (hr) 2013-11-08
US20050288276A1 (en) 2005-12-29
HRP20050342A2 (hr) 2006-04-30
ATE374600T1 (de) 2007-10-15
EP1558219B1 (en) 2007-10-03
RS20050292A (en) 2007-08-03
DK1558219T3 (da) 2007-10-29
SI21303A (sl) 2004-04-30
EP1558219A1 (en) 2005-08-03
NO20052408L (no) 2005-07-04
UA89349C2 (ru) 2010-01-25
WO2004035027A1 (en) 2004-04-29
PL376413A1 (en) 2005-12-27
EA008516B1 (ru) 2007-06-29
DE60316714T2 (de) 2008-07-17
CA2502582A1 (en) 2004-04-29
CA2502582C (en) 2010-08-03
PL206217B1 (pl) 2010-07-30
PT1558219E (pt) 2008-01-04
DE60316714D1 (de) 2007-11-15
SI1558219T1 (sl) 2008-02-29
ES2295626T3 (es) 2008-04-16
US20110319395A1 (en) 2011-12-29
NO20052408D0 (no) 2005-05-13
RS51488B (en) 2011-04-30
AU2003269792A1 (en) 2004-05-04
CY1107819T1 (el) 2013-06-19

Similar Documents

Publication Publication Date Title
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK1207756T3 (da) Anvendelse af spinosad eller en formulering, der omfatter spinosad
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
NO20065726L (no) Forbindelser og sammensetninger for avlevering av aktive forbindelser.
MY143795A (en) Tetrahydropyridoindole derivatives
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
DE60019334D1 (de) Antivirale arznei
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
WO2005065639A3 (en) Novel pharmaceutical compositions
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
HRP20020071B1 (hr) Farmaceutske kompozicije i pripravljanje istih
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
EA200500175A1 (ru) Соль морфин-6-глюкуронида
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
BR0316486A (pt) Composição farmacêutica que compreende um antagonista do ltb4 e um inibidor da cox-2 ou um inibidor combinado da cox1/2
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU